Evidence map›Paper›PMID 29277282›Full record

ArticleAlcohol (Fayetteville, N.Y.)2018

Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis.

John B Whitfield, Steven Masson, Suthat Liangpunsakul, Jessica Hyman, Sebastian Mueller, Guruprasad Aithal, Florian Eyer, Dermot Gleeson, Andrew Thompson, Felix Stickel and 23 more

Open access · greenAbstract readComparative StudyEvaluation StudyMulticenter Study
In one paragraph

Article in Alcohol (Fayetteville, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 6 countries.

John B WhitfieldGenetic Epidemiology, QIMR Berghofer Medical Research Institute, Queensland 4029, Australia. Electronic address: John.Whitfield@qimrberghofer.edu.au.
Steven MassonFaculty of Medical Sciences, Newcastle University Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom.
Suthat LiangpunsakulDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University, USA.
Jessica HymanCentenary Institute of Cancer Medicine and Cell Biology, Camperdown, NSW 2050, Australia.
Sebastian MuellerDepartment of Internal Medicine, Salem Medical Center and Center for Alcohol Research, University of Heidelberg, Zeppelinstraße 11-33, 69121 Heidelberg, Germany.
Guruprasad AithalNIHR Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals and University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom.
Florian EyerDivision of Clinical Toxicology, Department of Internal Medicine, 2 Klinikum rechts der Isar School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany.
Dermot GleesonThe Clinical Research Facility, O Floor, The Royal Hallamshire Hospital, Glossop Road, S10 2JF, United Kingdom.
Andrew ThompsonWolfson Centre for Personalised Medicine, Molecular & Clinical Pharmacology, University of Liverpool, 1-5 Brownlow Street, Liverpool L69 3GL, United Kingdom.
Felix StickelGastroenterology and Hepatology, University Hospital Zurich, Ramistrasse 100, CH-8901 Zurich, Switzerland.
Michael SoykaPrivatklinik Meiringen, Willigen, CH 3860 Meiringen, Switzerland.
Ann K DalyFaculty of Medical Sciences, Newcastle University Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom.
Heather J CordellInstitute of Genetic Medicine, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, United Kingdom.
Tiebing LiangDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University, USA.
Tatiana ForoudDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University, USA.
Lawrence LumengDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University, USA.
Munir PirmohamedWolfson Centre for Personalised Medicine, Molecular & Clinical Pharmacology, University of Liverpool, 1-5 Brownlow Street, Liverpool L69 3GL, United Kingdom.
Bertrand NalpasService Addictologie, CHRU Caremeau, 30029 Nîmes, France; DISC, Inserm, 75013 Paris, France.
Camille BenceCHRU de LILLE - Hôpital Claude Huriez, Rue M. Polonovski - CS 70001, 59 037 Lille Cedex, France.
Jean-Marc JacquetCentre Hospitalier Universitaire de Montpellier, Département des maladies infectieuses et tropicales, Montpellier, France.
Alexandre LouvetCHRU de LILLE - Hôpital Claude Huriez, Rue M. Polonovski - CS 70001, 59 037 Lille Cedex, France.
Romain MoirandCHU de Rennes, Unité d'Addictologie, F-35033 Rennes, France.
Pierre NahonAPHP, Liver Unit, Hospital Jean Verdier, Bondy, France; University Paris 13, Bobigny, France; Inserm U1162 "Functional Genomics of Solid Tumors", Paris, France.
Sylvie NaveauHU-Paris Sud, 157 Rue de la Porte de Trivaux, 92140 Clamart, France.
Pascal PerneyHôpital Universitaire Carémeau, Place du Pr. Robert Debré, 30029 Nîmes, France.
Philippe PodevinHôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013 Paris, France.
Paul S HaberDrug Health Services, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia; Faculty of Medicine, The University of Sydney, Sydney, NSW 2006, Australia.
Helmut K SeitzDepartment of Internal Medicine, Salem Medical Center and Center for Alcohol Research, University of Heidelberg, Zeppelinstraße 11-33, 69121 Heidelberg, Germany.
Christopher P DayFaculty of Medical Sciences, Newcastle University Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom.
Philippe MathurinCHRU de LILLE - Hôpital Claude Huriez, Rue M. Polonovski - CS 70001, 59 037 Lille Cedex, France.
Timothy M MorganDepartment of Veterans Affairs, VA Long Beach Healthcare System, 5901 East Seventh Street, Long Beach, CA 90822, USA.
Devanshi SethCentenary Institute of Cancer Medicine and Cell Biology, Camperdown, NSW 2050, Australia; Drug Health Services, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia; Faculty of Medicine, The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: d.seth@sydney.edu.au.
GenomALC Consortium
Indiana University · USNewcastle University · GBCentre Hospitalier Universitaire de Nîmes · FRHeidelberg University · DEHôpital Claude Huriez · FRUniversity of Liverpool · GBCentenary Institute · AUCentre Hospitalier Universitaire de Lille · FRCentre Hospitalier Universitaire de Montpellier · FRCentre Hospitalier Universitaire de Rennes · FRInserm · FRNIHR Nottingham Digestive Diseases Biomedical Research Unit · GBPrivatklinik Meiringen · CHQIMR Berghofer Medical Research Institute · AURoyal Hallamshire Hospital · GBRoyal Prince Alfred Hospital · AUSorbonne Université · FRTechnical University of Munich · DEUniversity Hospital of Zurich · CHUniversity of Sydney · AU

Funding

Genetic risk factors for alcoholic cirrhosis - genome-wide case-control studyU01AA018389 · NIAAA · SOUTHERN CALIFORNIA INST FOR RES/EDUC · PI CORDELL, HEATHER JANE, DALY, ANN · 2011 to 2018
$3.0M
Genetic risk factors for alcoholic cirrhosis - genome-wide case-control studyR01AA018389 · NIAAA · SOUTHERN CALIFORNIA INST FOR RES/EDUC · PI CORDELL, HEATHER JANE, DALY, ANN · 2019 to 2019
$336k
Medical Research Council MR/L006758/1Medical Research Council MR/N005953/1Medical Research Council MR/S000607/1NIAAA NIH HHS R01 AA018389NIAAA NIH HHS U01 AA018389
6 · The paper itself

Abstract

Laboratory tests can play an important role in assessment of alcoholic patients, including for evaluation of liver damage and as markers of alcohol intake. Evidence on test performance should lead to better selection of appropriate tests and improved interpretation of results. We compared laboratory test results from 1578 patients between cases (with alcoholic cirrhosis; 753 men, 243 women) and controls (with equivalent lifetime alcohol intake but no liver disease; 439 men, 143 women). Comparisons were also made between 631 cases who had reportedly been abstinent from alcohol for over 60 days and 364 who had not. ROC curve analysis was used to estimate and compare tests' ability to distinguish patients with and without cirrhosis, and abstinent and drinking cases. The best tests for presence of cirrhosis were INR and bilirubin, with areas under the ROC curve (AUCs) of 0.91 ± 0.01 and 0.88 ± 0.01, respectively. Confining analysis to patients with no current or previous ascites gave AUCs of 0.88 ± 0.01 for INR and 0.85 ± 0.01 for bilirubin. GGT and AST showed discrimination between abstinence and recent drinking in patients with cirrhosis, including those without ascites, when appropriate (and for GGT, sex-specific) limits were used. For AST, a cut-off limit of 85 units/L gave 90% specificity and 37% sensitivity. For GGT, cut-off limits of 288 units/L in men and 138 units/L in women gave 90% specificity for both and 40% sensitivity in men, 63% sensitivity in women. INR and bilirubin show the best separation between patients with alcoholic cirrhosis (with or without ascites) and control patients with similar lifetime alcohol exposure. Although AST and GGT are substantially increased by liver disease, they can give useful information on recent alcohol intake in patients with alcoholic cirrhosis when appropriate cut-off limits are used.

Indexed as

Alcohol AbstinenceClinical Enzyme TestsInternational Normalized RatioAdultAlcohol DrinkingArea Under CurveAspartate AminotransferasesBilirubinBiomarkersCase-Control StudiesEuropeFemalegamma-GlutamyltransferaseHumansLiver Cirrhosis, AlcoholicLiver Function TestsAspartate AminotransferasesBilirubinBiomarkersgamma-Glutamyltransferasegamma-glutamyltransferase, humanAbstinenceAlcoholAspartate aminotransferaseCirrhosisGamma glutamyl transferase

Identifiers

PMID29277282
PMCPMC5745811
OpenAlexW2760432762

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.